drugset / Trial / NCT01241162

Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma

NCT01241162

NaSingle-groupOpen-labelTreatment

Summary

This treatment study for relapsed high-risk neuroblastoma, Ewings sarcoma, osteogenic sarcoma, rhabdomyosarcoma or synovial sarcoma involves an autologous cancer testis (CT) antigen specific dendritic cell (DC) vaccine preceded by decitabine as a demethylating chemotherapy.

Timeline

Start
2010-08
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule 10 mg/m2 Intravenous
Subject autologous dendritic cell vaccine Vaccine
Background Hiltonol Other / unclassified Topical